Johnson & Johnson (NYSE:JNJ) is Ropes Wealth Advisors LLC’s 7th Largest Position

Ropes Wealth Advisors LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 7.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 60,604 shares of the company’s stock after buying an additional 3,970 shares during the period. Johnson & Johnson comprises 1.7% of Ropes Wealth Advisors LLC’s holdings, making the stock its 7th biggest holding. Ropes Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $8,523,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in JNJ. Altshuler Shaham Ltd bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $35,000. Lake Point Wealth Management raised its holdings in shares of Johnson & Johnson by 144.4% in the 1st quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock valued at $38,000 after purchasing an additional 169 shares in the last quarter. Advocacy Wealth Management Services LLC raised its holdings in shares of Johnson & Johnson by 38.2% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 300 shares of the company’s stock valued at $39,000 after purchasing an additional 83 shares in the last quarter. Lion Street Advisors LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $45,000. Finally, Joseph P. Lucia & Associates LLC raised its holdings in shares of Johnson & Johnson by 50.8% in the 1st quarter. Joseph P. Lucia & Associates LLC now owns 374 shares of the company’s stock valued at $49,000 after purchasing an additional 126 shares in the last quarter. 68.44% of the stock is owned by institutional investors.

Several research firms have recently commented on JNJ. Bank of America restated a “buy” rating on shares of Johnson & Johnson in a report on Monday. Wells Fargo & Co upgraded shares of Johnson & Johnson to a “hold” rating in a research note on Wednesday, April 22nd. Zacks Investment Research lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price objective for the company. in a research note on Tuesday, July 7th. UBS Group lowered shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $163.00 to $160.00 in a research note on Tuesday, April 28th. Finally, Citigroup boosted their price objective on shares of Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $163.38.

NYSE:JNJ opened at $150.01 on Thursday. The company has a market cap of $394.50 billion, a PE ratio of 18.79, a P/E/G ratio of 3.32 and a beta of 0.69. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $157.00. The company has a current ratio of 1.31, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41. The company’s 50 day moving average is $143.94 and its two-hundred day moving average is $144.00.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Thursday, July 16th. The company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.50 by $0.17. The business had revenue of $18.34 billion for the quarter, compared to the consensus estimate of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.70%. The business’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same period in the prior year, the firm earned $2.58 EPS. As a group, analysts expect that Johnson & Johnson will post 7.85 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a $1.01 dividend. This represents a $4.04 annualized dividend and a dividend yield of 2.69%. The ex-dividend date is Monday, August 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.54%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Marijuana Stocks Future Looks Bright

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.